Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)

Study Overview
=================
Brief Summary
-----------------
CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents who are admitted to the hospital for COVID-19 compared with patients who do not receive anticoagulants or antiplatelet agents.

Official Title
-----------------
Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient admitted for COVID-19 at the Hospital de la Santa Creu i Sant Pau, Positive COVID-19 polymerase chain reaction test Length of stay more than 24 hours Exclusion Criteria: No objective diagnose for COVID-19 Outpatient Lenght of stay less than 24hours
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients on previous oral anticoagulant treatment<br>Patients receiving chronic anticoagulation with vitamin K antagonists (VKA, warfarin or acenocumarol) or with DOACs (dabigatran, rivaroxaban, apixaban or edoxaban) for any indication | Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19<br>* Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy<br>|
| Patients on previous antiplatelet therapy<br>Patients receiving chronic antiplatelet therapy (aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, dipyridamol) for any indication | Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19<br>* Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy<br>|
| Patients without antithrombotic therapy<br>Patients receiving nor chronic oral anticoagulation neither chronic antiplatelet therapy | Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19<br>* Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  | From hospital admission to day 28 | 
| Transfer to the Intensive Care Unit (ICU) |  | From hospital admission to day 28 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thromboembolic complications | Venous thromboembolism, ischemic stroke, myocardial infarction or periferal arterial thrombosis during hospitalization for Covid19 | From hospital admission to day 28 | 
| Major bleeding complications | Any bleeding complication grade 3 or 5 according BARC classification | From hospital admission to day 28 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Covid19, Oral anticoagulant, VKA, DOAC, Antiplatelet therapy, Heparin, Low molecular-weight heparin